Cellectar Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Cellectar Biosciences, Inc. carries a market capitalization of 10.59M, placing it among publicly traded companies globally. Its enterprise value stands at -9.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.59M |
| Enterprise Value | -9.52M |
Share Statistics
Cellectar Biosciences, Inc. currently has 8.25M shares outstanding.
| Shares Outstanding | 8.25M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | -0.93 |
| P/OCF Ratio | -0.93 |
Financial Position
Cellectar Biosciences, Inc. maintains a current ratio of 6.66, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.66 |
| Quick Ratio | 6.49 |
| Debt / Equity | 5.13 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -125.99 |
| Return on Assets (ROA) | -88.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Cellectar Biosciences, Inc.'s stock has declined approximately -73.89277% over the past 52 weeks. The 50-day moving average sits at 2.13, while the 200-day moving average is 2.73.
| Beta (5Y) | N/A |
| 52-Week Price Change | -73.89277% |
| 50-Day Moving Average | 2.13 |
| 200-Day Moving Average | 2.73 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -23.50M, while operating income came in at -23.53M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -23.53M |
| Pretax Income | -22.32M |
| Net Income | -22.32M |
| EBITDA | -23.50M |
| EBIT | -23.53M |
| Earnings Per Share (EPS) | -3.41 |
Balance Sheet
Cellectar Biosciences, Inc. holds 33.99M in cash and equivalents against 1.53M in total debt, resulting in a net debt position of -33.99M. Total book value stands at 29.87M, with working capital of 29.64M providing operational flexibility.
| Cash & Cash Equivalents | 33.99M |
| Total Debt | 1.53M |
| Net Debt | -33.99M |
| Equity (Book Value) | 29.87M |
| Book Value Per Share | 3.62 |
| Working Capital | 29.64M |
Cash Flow
Cellectar Biosciences, Inc. produced -19.47M in operating cash flow over the past twelve months. After subtracting -9,258.00 in capital expenditures, free cash flow totaled -19.48M - equivalent to -2.98 per share.
| Operating Cash Flow | -19.47M |
| Capital Expenditures | -9,258.00 |
| Free Cash Flow | -19.48M |
| FCF Per Share | -2.98 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -46.99 |
| FCF Yield | -106.99 |
Stock Splits
Cellectar Biosciences, Inc.'s most recent stock split took place on June 23, 2025 with a 30:1 split ratio.
| Last Split Date | 6/23/2025 |
| Split Ratio | 30:1 |
Scores
Cellectar Biosciences, Inc. posts an Altman Z-Score of -9.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.88 |